PT-141 is a melanocortin agonist studied for central arousal signaling and MC4R-linked neurobiology.
Pre-loaded with a typical PT-141 (Bremelanotide) vial. Change any value to match what you actually have.
What published research and laboratory protocols actually document for PT-141 (Bremelanotide). Where a compound has no single microgram figure, we say so rather than inventing one.
| Reported amount | Frequency | Route | Where this figure comes from |
|---|---|---|---|
| 300 mcg – 10 mg | single study administration | subcutaneous | Subcutaneous PT-141 clinical pharmacology study Published clinical study exposure; not a recommendation and not research-grade product guidance. |
| 7.5 mg | single crossover study administration | intranasal | Intranasal PT-141 plus sildenafil study in men with erectile dysfunction Specific study design with intranasal PT-141; not comparable to vial reconstitution. |
| 1.75 mg | as labeled for the approved product | subcutaneous | FDA-approved bremelanotide product label context This describes Vyleesi, not research-grade PT-141 powder. |
People searching this page also look for: pt-141 peptide dosage for women, pt-141 peptide dosage, pt-141 peptide dosage for men, pt 141 peptide dosage for men, pt 141 peptide dosage for women, pt 141 peptide dosage, pt-141 peptide dosage chart, pt 141 peptide for men dosage.
PT-141, also known as bremelanotide, is a cyclic melanocortin analog studied for effects on central melanocortin pathways rather than vascular PDE5 signaling. Published studies examine subjective arousal, erectile-response measurements, pharmacokinetics, tolerability, and melanocortin receptor biology. Its research profile is distinct from metabolic melanocortins because MC4R-linked CNS signaling is a major focus.
Bremelanotide has an FDA-approved counterpart, Vyleesi, for a specific approved indication and labeled route. Research-grade PT-141 powder is not Vyleesi, is not an approved drug product, is Research Use Only, and is not for human consumption. Reported ranges below describe published clinical research or approved-product contexts as reference information only.
PT-141 activates melanocortin receptors, especially MC4R-relevant pathways in the central nervous system. Unlike PDE5 inhibitors, its studied effects are not primarily mediated by direct peripheral vasodilation. Research models focus on hypothalamic and limbic signaling, dopamine-related arousal circuits, and downstream autonomic effects. Because melanocortin receptors are distributed across tissues, pharmacodynamic work also tracks nausea, flushing, blood pressure, and route-dependent exposure.
melanocortin signaling · MC4R neurobiology · sexual arousal pharmacodynamics · CNS peptide signaling · peptide pharmacokinetics
PT-141 is studied by neuropharmacologists, sexual-medicine researchers, peptide chemists, and clinical pharmacology teams. Regulatory researchers distinguish approved bremelanotide products from research-grade material because formulation, labeling, and quality systems are not interchangeable.
Research-grade lyophilized PT-141 is commonly stored cold, dry, and protected from light; reconstituted research solutions are generally refrigerated and used within the supplier's stated stability window.
PT-141 has been studied with PDE5-inhibitor contexts, but combining centrally active melanocortin signaling with other pharmacology changes safety and interpretation. Research designs should distinguish approved bremelanotide products from RUO PT-141 and should not convert clinical exposure data into personal protocols.
The questions people actually search for, answered plainly.
Published PT-141 studies include subcutaneous and intranasal exposure ranges, and Vyleesi has its own approved label. Research-grade PT-141 is not Vyleesi and is not for human consumption.
Reconstitution examples often use 1-2 mL for 5-10 mg research vials. That only sets concentration for lab calculations.
PT-141 is not usually framed as a daily research compound in the core clinical literature. Frequency should be taken from the specific study being discussed.
A chart should keep subcutaneous study exposures, intranasal studies, and approved Vyleesi labeling in separate rows.
Clinical studies measure pharmacodynamic effects over hours after administration. Timing depends on route, formulation, and endpoint.
Bremelanotide is commonly cited around a 2-3 hour elimination half-life, though observed effects and study windows can extend beyond that.
It has been studied in combination contexts, but that is not a personal-use endorsement. RUO PT-141 should not be used as an approved drug substitute.
Primary literature on PT-141 (Bremelanotide). Open access where available.
Every citation above was programmatically checked against the NCBI PubMed database. Titles shown are the official indexed titles, not paraphrases.
Our support assistant walks through reconstitution, syringe units, storage, and how to read a Certificate of Analysis. Free, no account.
Read the guides